SCHEMBL967073

SCHEMBL967073

Cn1c2c(c3cc(F)ccc31)CCN(CC(=O)N1CCN(C3CCC3)CC1)C2

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.44
CNR2 P34972 1/20 0.44
PARP1 P09874 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HDAC6 Q9UBN7 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
SIGMAR1 Q99720 2/20 0.41
TACR1 P25103 1/20 0.40
MCHR1 Q99705 1/20 0.40
KCNH2 Q12809 1/20 0.40
HTR3A P46098 1/20 0.39
PER2 O15055 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967952 0.87 ALDH1A1 (0.45) CNR1CNR2SMN1; SMN2
SCHEMBL967951 0.87 PARP1 (0.52) PARP1SMN1; SMN2HDAC6SIGMAR1
SCHEMBL970353 0.79 PARP1 (0.52) CNR2PARP1SMN1; SMN2HDAC6HDAC1
SCHEMBL968695 0.78 PARP1 (0.47) PARP1SMN1; SMN2MCHR1
SCHEMBL970441 0.77 PARP1 (0.52) PARP1
SCHEMBL967730 0.76 PARP1 (0.49) CNR1PARP1SMN1; SMN2HDAC6HDAC1
SCHEMBL967543 0.76 TSHR (0.52) CNR1PARP1SMN1; SMN2HDAC6HDAC1
SCHEMBL969047 0.75 PARP1 (0.52) PARP1SMN1; SMN2SIGMAR1
SCHEMBL967196 0.74 PARP1 (0.51) PARP1SMN1; SMN2SIGMAR1
SCHEMBL968315 0.74 PARP1 (0.49) PARP1SMN1; SMN2HDAC6HDAC1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US claimed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 CNR1 9/4885CNR2 7/4885PARP1 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.